BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (Amex: DDD) announced today that it is collaborating with BioCryst Pharmaceuticals (Nasdaq: BCRX) to develop an oral formulation of peramivir using SCOLR’s proprietary CDT® drug delivery platform. SCOLR Pharma had previously announced a research collaboration with an undisclosed US based biopharmaceutical company on September 21, 2006.
